Sysmex (6869) · InitiativeFirst stated

Commercialization of cell culture medium measurement reagents for regenerative cellular medicine

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Development of Cell and Tissue Quality Evaluation Technology and Testing ToolsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2025-H1First statedAnnual report
「In June 2024, we began selling in Japan research-use reagents for measuring secreted proteins in cell culture media used in regenerative cell therapy, namely “HISCL™ VEGF Reagent (for research use)” and “HISCL™ PEDF Reagent (for research use)” (collectively, the “Products”). Use of the Products in the research and development and manufacturing of regenerative cell therapies is expected to contribute to the automation and efficiency of quality control testing for cell therapy products.」
We began selling HISCL™ VEGF Reagent and HISCL™ PEDF Reagent for the research and development and manufacturing of regenerative cell therapies, launching a new product initiative aimed at automating and improving the efficiency of quality control testing for cell therapy products.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Sysmex yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.